IMVT-1402 is an investigational medication being studied for the treatment of Graves’ Disease, an autoimmune disorder that affects the thyroid gland. This medication is designed to help regulate thyroid hormone levels in adult patients. It works by targeting the immune system’s response that causes the thyroid to produce excess hormones in Graves’ Disease.

Anti-thyroid drugs (ATDs) are standard medications used to treat Graves’ Disease. These medications help reduce the production of thyroid hormones. In this study, they are used alongside the investigational treatment to monitor how well IMVT-1402 works in helping patients potentially reduce their need for standard thyroid medications.

Graves’ Disease – An autoimmune disorder that affects the thyroid gland, causing it to produce excessive amounts of thyroid hormones. The condition typically develops gradually and leads to an overactive thyroid state known as hyperthyroidism. The immune system creates antibodies that stimulate the thyroid gland to grow and produce more thyroid hormones than the body needs. Common manifestations include enlargement of the thyroid gland, changes in energy levels, and alterations in metabolism. The condition can also affect the eyes, causing them to become irritated or protruding.